Between Curing and Torturing: Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy

References

• World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Online Annexes. World Health Organization; 2020.
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• World Health Organization. Safety of Medicines. Vol. 2. Geneva: World Health Organization; 2002.
   Google Scholar
• Schnippel K, Berhanu RH, Black A, et al. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infect Dis. 2016;16(1):1–10. doi:10.1186/s12879-016-1933-0
   Web of Science ®Google Scholar
• Wu S, Zhang Y, Sun F, et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2016;23(2):e521–e530. doi:10.1097/01.mjt.0000433951.09030.5a
   PubMed Web of Science ®Google Scholar
• Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(7):1871–1879. doi:10.1093/jac/dkx107
   PubMed Web of Science ®Google Scholar
• Xu HB, Jiang RH, Xiao HP. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2012;18(11):1104–1110. doi:10.1111/j.1469-0691.2011.03716.x
   Web of Science ®Google Scholar
• Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. Medicine. 2017;96(28). doi:10.1097/MD.0000000000007482
   Web of Science ®Google Scholar
• Zhang Y, Wu S, Xia Y, et al. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study. Med Sci Monit. 2017;23:2348–2356. doi:10.12659/MSM.904682
   PubMed Web of Science ®Google Scholar
• Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One. 2012;7(7):e40781. doi:10.1371/journal.pone.0040781
   PubMed Web of Science ®Google Scholar
• Mehta S, Das M, Laxmeshwar C, Jonckheere S, Thi SS, Isaakidis P. Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India. PLoS One. 2016;11(9):1–12. doi:10.1371/journal.pone.0162138
   Web of Science ®Google Scholar
• Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska J, Woźniak P, Sobolewski B. Treatment of the Fluoroquinolone-Associated Disability: the Pathobiochemical Implications. Oxid Med Cell Longev. 2017;2017:1–15. doi:10.1155/2017/8023935
   Web of Science ®Google Scholar
• Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6):1901522. doi:10.1183/13993003.01522-2019
   PubMed Web of Science ®Google Scholar
• Thomas BE, Shanmugam P, Malaisamy M, et al. Psycho-socio-economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PLoS One. 2016;11(1):1–15. doi:10.1371/journal.pone.0147397
   Web of Science ®Google Scholar
• Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open. 2016;6(2):e010035. doi:10.1136/bmjopen-2015-010035
   PubMed Web of Science ®Google Scholar
• Eton D, Ramalho de Oliveira D, Egginton J, et al. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2012:39. doi:10.2147/prom.s34681
   Google Scholar
• World Health Organization. WHOQOL User Manual. Geneva: World Health Organization; 1998. doi:10.4091/iken1991.9.1_123
   Google Scholar
• Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med. 1995;41(10):1383–1394. doi:10.1016/0277-9536(95)00116-O
   PubMed Web of Science ®Google Scholar
• Karimi M, Brazier J. Health, Health-Related Quality of Life, and Quality of Life: what is the Difference? Pharmacoeconomics. 2016;34(7):645–649. doi:10.1007/s40273-016-0389-9
   PubMed Web of Science ®Google Scholar
• Valadares RMC, Carvalho W, de Miranda SS. Association of adverse drug reaction to anti-tuberculosis medication with quality of life in patients in a tertiary referral hospital. Rev Soc Bras Med Trop. 2020;53(August):1. doi:10.1590/0037-8682-0207-2019
   Web of Science ®Google Scholar
• Masumoto S, Yamamoto T, Ohkado A, Yoshimatsu S, Querri AG, Kamiya Y. Factors associated with health-related quality of life among pulmonary tuberculosis patients in Manila, the Philippines. Qual Life Res. 2014;23(5):1523–1533. doi:10.1007/s11136-013-0571-x
   Web of Science ®Google Scholar
• Sineke T, Evans D, Schnippel K, et al. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes. 2019;17(1). doi:10.1186/s12955-019-1155-4
   Web of Science ®Google Scholar
• Lange C, Abubakar I, Alffenaar JWC, et al. Management of patients with multidrug-resistant/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63. doi:10.1183/09031936.00188313
   PubMed Web of Science ®Google Scholar
• Alene KA, Clements ACA, McBryde ES, et al. Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Infect. 2018;77(5):357–367. doi:10.1016/j.jinf.2018.07.007
   PubMed Web of Science ®Google Scholar
• Datta S, Gilman RH, Montoya R, et al. Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study. Eur Respir J. 2020;56(2):1900495. doi:10.1183/13993003.00495-2019
   Web of Science ®Google Scholar
• Ahmad N, Javaid A, Sulaiman SAS, et al. Effects of multidrug resistant tuberculosis treatment on patients’ health related quality of life: results from a follow up study. PLoS One. 2016;11(7):1–16. doi:10.1371/journal.pone.0159560
   Web of Science ®Google Scholar
• Jaber AAS, Ibrahim B. Health-related quality of life of patients with multidrug-resistant tuberculosis in Yemen: prospective study. Health Qual Life Outcomes. 2019;17(1):1–14. doi:10.1186/s12955-019-1211-0
   Web of Science ®Google Scholar
• Kuchukhidze G, Kumar AMV, Colombani P, et al. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Heal Action. 2017;7(1).
   Google Scholar
• Kassa GM, Teferra AS, Wolde HF, Muluneh AG, Merid MW. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study. BMC Infect Dis. 2019;19(1):1–11. doi:10.1186/s12879-019-4447-8
   Web of Science ®Google Scholar
• Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia. Patient Prefer Adherence. 2016;10:2369–2377. doi:10.2147/PPA.S116860
   Web of Science ®Google Scholar
• Ting NCH, El-Turk N, Chou MSH, Dobler CC. Patient-perceived treatment burden of tuberculosis treatment. PLoS One. 2020;15(10 October):1–13. doi:10.1371/journal.pone.0241124
   Web of Science ®Google Scholar
• Sagwa E, Mantel-Teeuwisse AK, Ruswa N, et al. The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia. South Med Rev. 2012;5(1):6–13.
   PubMedGoogle Scholar
• Kastien-Hilka T, Rosenkranz B, Sinanovic E, Bennett B, Schwenkglenks M. Health-related quality of life in South African patients with pulmonary tuberculosis. PLoS One. 2017;12(4):1–20. doi:10.1371/journal.pone.0174605
   Web of Science ®Google Scholar
• Nuwagira E, Stadelman A, Baluku JB, et al. Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study. Trop Med Health. 2020;48(1). doi:10.1186/s41182-020-00221-y
   Web of Science ®Google Scholar
• Isaakidis P, Paryani R, Khan S, Mansoor H, Manglani M. Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India. PLoS One. 2013;8(7):e68869. doi:10.1371/journal.pone.0068869
   PubMed Web of Science ®Google Scholar
• Gebreweld FH, Kifle MM, Gebremicheal FE, et al. Factors influencing adherence to tuberculosis treatment in Asmara, Eritrea: a qualitative study. J Heal Popul Nutr. 2018;37(1):1–9. doi:10.1186/s41043-017-0132-y
   PubMed Web of Science ®Google Scholar
• Sturdy A, Goodman A, Joś RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66(8):1815–1820. doi:10.1093/jac/dkr221
   PubMed Web of Science ®Google Scholar
• Reuter A, Tisile P, Von Delft D, et al. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis. 2017;21(11):1114–1126. doi:10.5588/ijtld.17.0468
   PubMed Web of Science ®Google Scholar
• Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK, Das M, Daftary A. “When treatment is more challenging than the disease”: a qualitative study of MDR-TB patient retention. PLoS One. 2016;11(3):1–12. doi:10.1371/journal.pone.0150849
   Web of Science ®Google Scholar
• Horter S, Stringer B, Greig J, et al. Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan. BMC Infect Dis. 2016;16(1):1–15. doi:10.1186/s12879-016-1723-8
   Web of Science ®Google Scholar
• Laxmeshwar C, Stewart AG, Dalal A, et al. Beyond ‘cure’ and ‘treatment success’: quality of life of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(1):73–81. doi:10.5588/ijtld.18.0149
   PubMed Web of Science ®Google Scholar
• Deshmukh RD, Dhande DJ, Sachdeva KS, et al. Patient and provider reported reasons for lost to follow up in MDRTB treatment: a qualitative study from a drug resistant TB Centre in India. PLoS One. 2015;10(8):1–11. doi:10.1371/journal.pone.0135802
   Web of Science ®Google Scholar
• Dos Santos FL, Souza LLL, Bruce ATI, et al. Patients’ perceptions regarding multidrug-resistant tuberculosis and barriers to seeking care in a priority city in Brazil during COVID-19 pandemic: a qualitative study. PLoS One. 2021;16(4 April):1–19. doi:10.1371/journal.pone.0249822
   Web of Science ®Google Scholar
• Walker IF, Khan AM, Khan AM, et al. Depression among multidrug-resistant tuberculosis patients in Punjab, Pakistan: a large cross-sectional study. Int J Tuberc Lung Dis. 2018;22(7):773–778. doi:10.5588/ijtld.17.0788
   PubMed Web of Science ®Google Scholar
• Huque R, Elsey H, Fieroze F, et al. “death is a better option than being treated like this”: a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients. BMC Public Health. 2020;20(1):1–13. doi:10.1186/s12889-020-08986-x
   Web of Science ®Google Scholar
• Sanchez-Padilla E, Marquer C, Kalon S, et al. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study. Int J Tuberc Lung Dis. 2014;18(2):160–167. doi:10.5588/ijtld.13.0369
   Web of Science ®Google Scholar
• Brust JCM, Shah NS, Van Der Merwe TL, et al. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in kwazulu-natal, South Africa. J Acquir Immune Defic Syndr. 2013;62(4):436–440. doi:10.1097/QAI.0b013e31828175ed
   Web of Science ®Google Scholar
• Carroll MW, Lee M, Cai Y, et al. Frequency of adverse reactions to first-and second line antituberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis. 2019;16(7):961–966. doi:10.5588/ijtld.11.0574.Frequency
   Google Scholar
• Wang Y, Chen H, Mcneil EB, Lu X. Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: a Cross-Sectional Study. Patient Prefer Adherence. 2019;1641–1653.
   Web of Science ®Google Scholar
• Tupasi TE, Marie A, Garfin CG, et al. Factors Associated with Loss to Follow-up during Treatment for. Emerg Infect Dis. 2016;22(3):2012–2014. doi:10.3201/eid2211.160728
   Web of Science ®Google Scholar
• World Health Organization. Adherence to Long-Term Therapy: Evidence for Action. Geneva; 2003.
   Google Scholar
• Woldeyohannes D, Tekalegn Y, Sahiledengle B. Predictors of mortality and loss to follow-up among drug resistant tuberculosis patients in Oromia Hospitals, Ethiopia: a retrospective follow-up study. PLoS One. 2021;71:1–15. doi:10.1371/journal.pone.0250804
   Web of Science ®Google Scholar
• Iweama CN, Agbaje OS, Christian P, et al. Nonadherence to tuberculosis treatment and associated factors among patients using directly observed treatment short-course in north-west Nigeria: a cross-sectional study. SAGE Open Med. 2021;9:205031212198949. doi:10.1177/2050312121989497
   Web of Science ®Google Scholar
• Dela AI, Tank NKD, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study. Lung India. 2017;34(6):522–526. doi:10.4103/0970-2113.217569
   Web of Science ®Google Scholar
• Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MID. Tupasi and TE. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015;16(7):955–960. doi:10.5588/ijtld.11.0502.Impact
   Google Scholar
• Batte C, Namusobya MS, Kirabo R, Mukisa J, Batte C. Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital. Kampala Uganda. 2021;21(1):238–247.
   Google Scholar
• Nair D, Velayutham B, Kannan T, et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Heal Action. 2017;7(1):254.
   Web of Science ®Google Scholar
• Bastard M, Sanchez-padilla E, Hewison C, et al. Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and Abkhazia. J Infect Dis. 2015;211(10):1607–1615. doi:10.1093/infdis/jiu551
   Web of Science ®Google Scholar
• Rupani MP, Dave JD, Parmar VB, Singh MP, Parikh KD. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India. Natl Med J India. 2020;33(1):10–14. doi:10.4103/0970-258X.308234
   Web of Science ®Google Scholar
• Patel SV, Nimavat KB, Alpesh PB, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDR TB) in Western India: a prospective study. J Infect Public Health. 2016;9(4):478–484. doi:10.1016/j.jiph.2015.11.011
   PubMed Web of Science ®Google Scholar
• Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013. Clin Microbiol Infect. 2018;24(4):381–388. doi:10.1016/j.cmi.2017.07.008
   PubMed Web of Science ®Google Scholar
• Gelmanova IY, Keshavjee S, Golubchikova VT, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ. 2018;85(9):703–711. doi:10.2471/BLT
   Google Scholar
• Tola HH, Holakouie-na K, Mansournia MA. Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in. Sci Rep. 2019;9(1):1–10. doi:10.1038/s41598-019-56553-1
   Web of Science ®Google Scholar
• Tran VT, Barnes C, Montori VM, Falissard B, Ravaud P. Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. BMC Med. 2015;13(1):1–15. doi:10.1186/s12916-015-0356-x
   PubMed Web of Science ®Google Scholar
• Sav A, King MA, Whitty JA, et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. Heal Expect. 2015;18(3):312–324. doi:10.1111/hex.12046
   PubMed Web of Science ®Google Scholar
• Krska J, Katusiime B, Corlett SA. Patient experiences of the burden of using medicines for long-term conditions and factors affecting burden: a cross-sectional survey. Heal Soc Care Commun. 2018;26(6):946–959. doi:10.1111/hsc.12624
   Web of Science ®Google Scholar
• Gould E, Mitty E. Medication Adherence is a Partnership, Medication Compliance is Not. Geriatr Nurs (Minneap). 2010;31(4):290–298. doi:10.1016/j.gerinurse.2010.05.004
   PubMed Web of Science ®Google Scholar
• Lalor MK, Greig J, Allamuratova S, et al. Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment, Uzbekistan: a Retrospective Cohort Analysis. PLoS One. 2013;8(11):e78364. doi:10.1371/journal.pone.0078364
   Web of Science ®Google Scholar
• Tola HH, Karimi M, Yekaninejad MS. Effects of sociodemographic characteristics and patients’ health beliefs on tuberculosis treatment adherence in Ethiopia: a structural equation modelling approach. Infect Dis Poverty. 2017;6(1):1–10. doi:10.1186/s40249-017-0380-5
   Web of Science ®Google Scholar
• Tola HH, Shojaeizadeh D, Tol A, et al. Psychological and educational intervention to improve tuberculosis treatment adherence in Ethiopia based on health belief model: a cluster randomized control trial. PLoS One. 2016;11(5):1–15. doi:10.1371/journal.pone.0155147
   Web of Science ®Google Scholar
• Abiz M, Robabi H, Salar A, Saeedinezhad F. The Effect of Self-Care Education on the Quality of Life in Patients with Pulmonary Tuberculosis. Med Surg Nurs J. 2020;9(2). doi:10.5812/msnj.108877
   Google Scholar
• Deshmukh RD, Dhande DJ, Sachdeva KS, Sreenivas AN, Kumar AMV, Parmar M. Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. Indian J Tuberc. 2018;65(1):41–47. doi:10.1016/j.ijtb.2017.05.003
   PubMedGoogle Scholar
• Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related Beliefs about Medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633. doi:10.1371/journal.pone.0080633
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao X. Effects of the Health Belief Model-Based Intervention on Anxiety, Depression, and Quality of Life in Chronic Obstructive Pulmonary Disease. Neuroimmunomodulation. 2021;28(3):129–136. doi:10.1159/000512993
   Web of Science ®Google Scholar
• Toczek A, Cox H, Du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(3):299–307. doi:10.5588/ijtld.12.0537
   PubMed Web of Science ®Google Scholar
• Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645–662. doi:10.5588/ijtld.18.0622
   PubMed Web of Science ®Google Scholar
• Curry International Tuberculosis Centre & California Departement of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. Third ed. USA: CITC & the State of California Department of Public Health, Tuberculosis Control Branch (CDPH); 2016.
   Google Scholar
• Choi R, Jeong BH, Koh WJ, Lee SY. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med. 2017;37(2):97–107. doi:10.3343/alm.2017.37.2.97
   PubMed Web of Science ®Google Scholar
• Wilby KJ, Ensom MHH, Marra F. Review of Evidence for Measuring Drug Concentrations of First-Line Antitubercular Agents in Adults. Clin Pharmacokinet. 2014;53(10):873–890. doi:10.1007/s40262-014-0170-1
   PubMed Web of Science ®Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–854. doi:10.1007/s40265-014-0222-8
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ohno M, Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics. 2014;15(5):601–607. doi:10.2217/pgs.14.38
   PubMed Web of Science ®Google Scholar
• Olsson S. Overview of pharmacovigilance in resource limited settings: challenges and opportunities. Clin Ther. 2013;35(8):e122–e123. doi:10.1016/j.clinthera.2013.07.379
   Google Scholar
• Silva DR, Mello FC, Migliori GB. Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol. 2020;46(2):1–8. doi:10.36416/1806-3756/e20200009
   Web of Science ®Google Scholar
• World Health Organization. What is New in the WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment? Geneva: World Health Organization; 2019. doi:10.4103/ijmr.IJMR_579_19
   Google Scholar
• Stringer B, Lowton K, James N, Nyang’wa BT. Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO. BMJ Open. 2021;11(9):1–6. doi:10.1136/bmjopen-2020-043954
   Web of Science ®Google Scholar
• Grace A, Mittal A, Jain S, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;12.
   Web of Science ®Google Scholar
• Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a Phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021;21(7):975–983. doi:10.1016/S1473-3099(20)30770-2
   PubMed Web of Science ®Google Scholar
• Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564–574. doi:10.1183/13993003.00724-2015
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. N Engl J Med. 2014;371(8):723–732. doi:10.1056/nejmoa1313865
   PubMed Web of Science ®Google Scholar
• Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019;7(12):1048–1058. doi:10.1016/S2213-2600(19)30366-2
   PubMed Web of Science ®Google Scholar
• Fu L, Weng T, Sun F, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;111:138–147. doi:10.1016/j.ijid.2021.08.055
   PubMed Web of Science ®Google Scholar